Calquence tablet formulation approved in the US across current indications
New formulation can be co-administered with gastric acid-reducing agents. Tablet offers equivalent efficacy, safety and consistent dosing compared to current capsule.AstraZeneca’s new tablet formulation of Calquence (acalabrutinib) has been approved in the US for all current indications, including adult patients with chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) and for patients with relapsed or refractory mantle cell lymphoma (MCL), which is approved under accelerated approval based on overall response rate. The approval by the US Food and Drug Administration (